Audit of the reimbursed medicines list for haemato-oncology diagnoses

Summary

The tender is for an audit of the reimbursed medicines list across 17 haemato-oncology diagnoses. The work includes preparing algorithms based on international treatment guidelines, assessing whether medicines on the list comply with those guidelines, and identifying necessary changes by diagnosis, treatment regimen and patient group. The contractor must provide findings and recommendations, prepare a guideline summary for each diagnosis, identify medicines to add to or remove from the list, and define priority actions for improving it. The results must be submitted as final documentation and presented to the contracting authority. The contract runs until 31 December 2026 or until all obligations have been fulfilled. The budget ceiling is EUR 28,600 excluding VAT. Price is the sole award criterion, and the lowest total-priced bid will be selected. The bidder must have the specified experience in clinical guideline analysis or development and provide at least one suitably educated and experienced specialist.